Company: BDRX
Filing Date: 2025-06-02
Form Type: 424B3
Source: 0001214659-25-008713
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-06-02
Form: 424B3
Chunk 2
---
        5.7 |
| Cash in escrow for eRapa Phase 3 program      |     |        4.4 |
|                                               |     |       10.1 |
| Undrawn CPRIT grant for eRapa Phase 3 program |     |       11.9 |
| Debt                                          |     |        0.5 |

The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially
funded. Based on its latest projections, the Company has sufficient working capital to fund operations into the first quarter of 2026.

Issued shares, total voting rights, market capitalization
As of May 29, 2025, there were 50,506,308,922 ordinary shares, equivalent to 5,050,630 American Depositary Shares (ADSs), outstanding.
The Company holds zero shares in treasury and therefore the number of voting rights is the same as the number of ordinary shares outstanding.

Based on the closing share price on May 29, 2025 of $1.06 per ADS, the Company’s
market capitalization was $5.4 million.

eRapa Phase 3 program
The Phase 3 study of eRapa in FAP is in the final stages of implementation. It will be a double-blind placebo-controlled trial in 168
patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in approximately 30 clinical sites across the US and
Europe. The US component of the study will be conducted by LumaBridge, based in San Antonio, Texas and the European component will be
conducted by Precision for Medicine LLC. All planned US sites and the majority of European sites have been identified. Recruitment is
expected to begin in the next few weeks.

About FAP
FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic
option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of
care. If untreated, FAP typically leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with
a reported prevalence of one in 5,000 to 10,000 in the US and one in 11,300 to 37,600 in Europe. Importantly,
mTOR has been shown to be over-expressed in F